Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In Process Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

10x Genomics (TXG) Long-Term Debt Repayments (2020)

10x Genomics' Long-Term Debt Repayments history spans 1 years, with the latest figure at $31.3 million for Q1 2020.

On a quarterly basis, Long-Term Debt Repayments changed N/A to $31.3 million in Q1 2020 year-over-year; TTM through Dec 2020 was $31.3 million, a N/A change, with the full-year FY2020 number at $31.3 million, changed N/A from a year prior.
Long-Term Debt Repayments hit $31.3 million in Q1 2020 for 10x Genomics.
Over the last five years, Long-Term Debt Repayments for TXG hit a ceiling of $31.3 million in Q1 2020 and a floor of $31.3 million in Q1 2020.